According to a recent LinkedIn post from JenaValve Technology Inc, the company plans to showcase its newly U.S. FDA‑approved Trilogy System at the AATS Annual Meeting in Chicago in May 2026. The post invites attendees to visit its booth to learn more about treatment options for high‑risk patients with symptomatic severe aortic regurgitation.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post highlights JenaValve’s emphasis on the evolving treatment landscape in structural heart disease and directs clinicians to important safety information via the company’s website. For investors, this visibility at a major cardiothoracic surgery forum may support physician awareness and adoption of Trilogy, which could be a key driver for future revenue once commercial distribution and reimbursement pathways are fully established.
Participation at AATS also suggests JenaValve is targeting high‑acuity centers and opinion‑leading cardiac surgeons and interventional cardiologists, a critical audience for premium device utilization. While the post does not disclose sales figures, pricing, or commercialization timelines, it implies that the regulatory risk on this product has been partly de‑risked by FDA approval, shifting the focus toward execution in market access, clinical uptake, and competitive positioning in the aortic valve replacement segment.